Promoting Competition
and Investment in the
U.S. Life Sciences Ecosystem
The U.S. life sciences ecosystem depends on mergers and acquisitions (M&A) to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients.
PARTNERS
ABOUT US
PULSE is dedicated to raising awareness about the vital role of mergers and acquisitions (M&A) as well as other collaborations to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients. Our members represent frontline researchers, employees and leaders of life sciences companies of all sizes that support a diverse, vibrant life sciences ecosystem at the national level and in local communities. PULSE will help advance a national dialogue focused on fostering innovation across the life sciences while supporting a competitive U.S. market that delivers next generation treatments and cures
for patients.
LATEST NEWS
Life Sciences M&A – A Necessary and Anticipated Step in Advancing Early-Stage Breakthroughs
For many early-stage life sciences companies, mergers and acquisitions (M&A) and other collaborations are fundamental to advancing promising new discoveries. An acquisition by a larger, more established company often represents a necessary and anticipated milestone in an early-stage company’s journey to bring a new breakthrough from the lab to the patient.
New BIO & TEConomy Report and the Importance of Life Sciences M&A
A recent report from BIO and TEConomy notes that decades of growth in the life sciences have been “rooted in, and enabled by, basic and applied research and development activities; development of, and access to, a qualified and highly skilled workforce; [and]...
Innovations Advanced by M&A: A Breakthrough Precision Therapy for Rare Cancers
In the case of Ignyta’s acquisition by Roche, M&A played a pivotal role in accelerating a new precision therapy to patients battling rare forms of cancer.
Founded in 2011 by Drs. David Lim and Gary Firestein, Ignyta initially focused on developing diagnostics for rheumatoid arthritis. However, after facing early scientific setbacks, the company pivoted its focus to advancing entrectinib, a promising investigational therapy for certain types of cancer caused by rare genetic mutations, along with developing diagnostic tests to help identify these mutations.